Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

45
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

8.3K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.3K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

280
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
280
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

429
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
429
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indications of over- and undertreatment of hypothyroidism in primary care: a scoping review and evidence mapping.

Scandinavian journal of primary health care·2026
Same author

Antithyroid drug treatment in pregnancy: A first report from the Danish PRETHYR multicenter study.

The Journal of clinical endocrinology and metabolism·2026
Same author

Glucose-Dependent Effects of Exogenous Glucagon-Like Peptide-2 on Circulating Glucagon Levels in Healthy Men.

Journal of the Endocrine Society·2026
Same author

Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study.

Diabetes, obesity & metabolism·2025
Same author

Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multi-centre RCT.

European thyroid journal·2025
Same author

Genome-wide association study and polygenic risk prediction of hypothyroidism.

Nature genetics·2025

Related Experiment Video

Updated: Feb 25, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K

Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment

Allan Carlé1, Jens Faber2,3, Rudi Steffensen4

  • 1Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.

European Thyroid Journal
|August 9, 2017
PubMed
Summary

Hypothyroid patients with specific DIO2 and MCT10 gene variations show a stronger preference for combination therapy (levothyroxine + liothyronine) over levothyroxine alone. This finding may guide future personalized treatment recommendations.

Keywords:
HypothyroidismL-T3 treatmentRandomized clinical trialSingle nucleotide polymorphismsThyroid failure

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K

Related Experiment Videos

Last Updated: Feb 25, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.6K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K

Area of Science:

  • Endocrinology
  • Genetics
  • Pharmacogenomics

Background:

  • Levothyroxine (L-T4) monotherapy is standard for hypothyroidism, but some patients prefer combination therapy with liothyronine (L-T3).
  • The genetic basis for individual treatment preference remains largely unexplored.

Purpose of the Study:

  • To investigate the role of specific gene polymorphisms in patient preference for L-T4 + L-T3 combination therapy versus L-T4 monotherapy.
  • To identify genetic markers that predict a better response to combination thyroid hormone replacement therapy.

Main Methods:

  • A prospective, double-blind, cross-over study involving 45 hypothyroid patients euthyroid on L-T4 therapy.
  • Patients were randomized to receive either L-T4 monotherapy or L-T4 + L-T3 combination therapy for 3 months each.
  • Analysis included genotyping for polymorphisms in the iodothyronine deiodinase (DIO2) and monocarboxylate transporter (MCT10) genes.

Main Results:

  • 60% of patients preferred the L-T4 + L-T3 combination therapy.
  • A significant association was found between combined polymorphisms in DIO2 (rs225014) and MCT10 (rs17606253) and preference for combination therapy (p = 0.009).
  • Patients with both polymorphisms were 100% more likely to prefer combination therapy.

Conclusions:

  • Combined polymorphisms in DIO2 and MCT10 influence patient preference for combination thyroid hormone therapy.
  • Genetic profiling may help personalize thyroid hormone replacement strategies, potentially identifying patients who would benefit most from L-T4 + L-T3 therapy.